【摘要】 目的在急性非ST抬高型心肌梗死(NSTEMI)介入术后应用尼可地尔治疗的效果。方法从该院2016年10月—2017年10月接收并行经皮冠状动脉介入治疗的NSTEMI患者中,随机抽取120例作为该次研究的对象,随机分作甲乙两组,每组60例。甲组术后均口服安慰剂,乙组术后则口服尼可地尔,对比两组NSTEMI患者的临床效果。结果①术后3 d、1周,乙组的CTnI水平均显著低于甲组,对比差异有统计学意义(t=8.576 9、10.453 5,P<0.05)。②甲组临床有效率为66.67%,低于乙组的85.0%,对比差异有统计学意义(χ~2=5.502 7,P=0.018 9)。③甲组室性早搏、非持续性室速或室颤的发生率分别为75.0%、30.0%,均分别高于乙组的33.33%、10.0%,差异有统计学意义(χ~2=20.979 0、7.500 0,P<0.05)。结论在急性NSTEMI介入术后治疗中服用尼可地尔,有助于调节患者的CTnI水平,降低术后不良心血管事件的发生率,值得积极推广与使用。更多还原

【Abstract】 Objective To evaluate the effect of nicorandil in patients with acute non-ST elevation myocardial infarction(NSTEMI). Methods From the patients with NSTEMI who received parallel percutaneous coronary intervention from October 2016 to October 2017, 120 patients were randomly selected as the subjects of this study. They were randomly divided into two groups, 60 patients in each group. Group A was given oral placebo after operation, and group B was given nicorandil after operation to compare the clinical effects of NSTEMI patients. Results 1.At 3 days and 1 week after operation, the CTnI level of group B was significantly lower than that of group A, and the correlation was statistically significant(t=8.576 9, 10.453 5, P<0.05). 2.The clinical effective rate of group A was 66.67%, which was lower than that of group B(85.0%). The comparison was statistically significant(χ~2=5.502 7, P=0.018 9). 3.The incidence of ventricular premature beats, non-sustained ventricular tachycardia or ventricular fibrillation in group A was 75.0% and30.0%, respectively, which were higher than those of group B, 33.33% and 10.0%, respectively. The difference was statistically significant(χ~2=20.979 0, 7.500 0, P<0.05). Conclusion The use of nicorandil in the treatment of acute NSTEMI intervention is helpful to regulate the CTnI level of patients and reduce the incidence of postoperative adverse cardiovascular events. It is worthy of active promotion and use.更多还原